Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cross-reactivity00:42

Cross-reactivity

Overview
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Hybridoma Technology01:31

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Antibody Structure01:10

Antibody Structure

Overview
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Autoreactivity vs autoimmunity: characteristics of autoantigen-specific CD4 T-cells in rheumatoid arthritis and health.

Arthritis & rheumatology (Hoboken, N.J.)·2026
Same author

Chasing the target: reports from the Advances in Targeted Therapies meeting, 2025.

Annals of the rheumatic diseases·2026
Same author

Anti-CD52 therapy of rheumatic diseases: Revisited in the era of immune reset.

Autoimmunity reviews·2026
Same author

Immune reset and immune retune: approaching cure?

Nature reviews. Rheumatology·2026
Same author

Autoantibodies as predictors of progression to rheumatoid arthritis: a systematic review and meta-analysis.

RMD open·2026
Same author

Intra-articular injection of autologous tolerogenic dendritic cells modifies the synovial immune landscape in rheumatoid and inflammatory arthritis.

Annals of the rheumatic diseases·2026

Related Experiment Video

Updated: Jun 22, 2026

Anti-Nuclear Antibody Screening Using HEp-2 Cells
13:01

Anti-Nuclear Antibody Screening Using HEp-2 Cells

Published on: June 23, 2014

Antibody engineering to develop new antirheumatic therapies.

John D Isaacs1

  • 1Wilson Horne Immunotherapy Centre and Musculoskeletal Research Group, Institute of Cellular Medicine, Newcastle University, Newcastle-Upon-Tyne NE2 4HH, UK. j.d.isaacs@ncl.ac.uk

Arthritis Research & Therapy
|June 4, 2009
PubMed
Summary

Rheumatology treatments have advanced significantly, shifting from oral immunosuppressants to targeted biological therapies. Antibody engineering drives these innovations, improving patient remission and future cure possibilities for rheumatoid arthritis.

More Related Videos

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

Antibody Transfection into Neurons as a Tool to Study Disease Pathogenesis
06:56

Antibody Transfection into Neurons as a Tool to Study Disease Pathogenesis

Published on: September 26, 2012

Related Experiment Videos

Last Updated: Jun 22, 2026

Anti-Nuclear Antibody Screening Using HEp-2 Cells
13:01

Anti-Nuclear Antibody Screening Using HEp-2 Cells

Published on: June 23, 2014

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

Antibody Transfection into Neurons as a Tool to Study Disease Pathogenesis
06:56

Antibody Transfection into Neurons as a Tool to Study Disease Pathogenesis

Published on: September 26, 2012

Area of Science:

  • Rheumatology
  • Immunology
  • Biotechnology

Background:

  • The past 15 years have seen a major shift in rheumatology therapeutics.
  • This transition involves moving from oral immunosuppressive drugs to parenteral targeted biological therapies.
  • Advances in molecular biology and protein engineering underpin these developments.

Purpose of the Study:

  • This review focuses on antibody engineering.
  • It highlights its role as a key driver in current and developing antirheumatic treatments.
  • The review examines the impact of these therapies on rheumatoid arthritis pathogenesis.

Main Methods:

  • Review of scientific literature on therapeutic advancements in rheumatology.
  • Analysis of the role of molecular biology and protein engineering in drug development.
  • Focus on antibody engineering techniques and their application in antirheumatic treatments.

Main Results:

  • Newer biological agents offer increased potency and improved safety profiles.
  • These advancements enable more aggressive treatment strategies, leading to higher rates of disease remission.
  • The development of targeted therapies has shifted the paradigm towards potential disease 'cure'.

Conclusions:

  • Antibody engineering is central to the therapeutic revolution in rheumatology.
  • Targeted biological therapies represent a significant improvement over traditional oral immunosuppressants.
  • Future developments in antibody engineering hold promise for achieving disease remission and potential cures in rheumatoid arthritis.